[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Article
May 8, 1967

WASHINGTON NEWS

JAMA. 1967;200(6):35-37. doi:10.1001/jama.1967.03120190027004

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

The Food and Drug Administration has moved to place broad new restrictions on prescription drug advertising, including greater prominence and detail for adverse reactions and contraindications.

The proposals eventually are expected to be subject to hearings before FDA. One of the issues splitting FDA and the drug industry in the new proposals is whether drug advertising should be considered as mainly educational in nature, or mainly promotional.

The Pharmaceutical Manufacturers Association had no immediate official comment on the FDA's proposals, but PMA president C. Joseph Stetler told reporters that in his opinion the recommendations would result in a distortion of advertising principles. Medical articles, not ads, are the proper vehicle for comprehensive information on efficacy and side effects of drugs, he said. If FDA insists on making the proposals a part of its regulations, the PMA is expected to oppose them formally.

Here is a summary

×